Answers are grounded in this paper and cite their sources.
Background and objectives This study aimed to investigate the heterogeneous clinicopathological features and associated prognoses of anti-HMGCR patients with immune-mediated necrotizing myopathy (IMNM). Methods This study enrolled patients with anti-HMGCR-positive detected both by ELISA and Western blotting assays. The clinical, pathological data, and exome sequencing (WES) information of the patients were collected. Patients whose clinical and pathological features met the 2016 European Neuromuscular Centre criteria for IMNM were classified as having typical IMNM. Conversely, patients presenting with atypical clinical manifestations, such as asymptomatic hyperCKemia, muscular dystrophy-like phenotypes, or exhibiting at least one atypical histopathological feature (e.g., ragged red fibers or COX-negative fibers in patients under 60 years old, lipid aggregation, glycogen accumulation, or rimmed vacuoles) were assigned to the atypical IMNM group. Time-to-remission was used to evaluate the prognosis of the patients. Results Seventy-one patients were positive for anti-HMGCR antibodies by preliminary ELISA screening, and 65 patients were confirmed to be anti-HMGCR-positive by Western blotting assay. Fifteen of the 65 patients (23.1%) exhibited atypical IMNM, and no pathogenic mutations were found in these 15 patients by WES. Patients with atypical IMNM had a younger age of onset (29.3 ± 17.5 vs. 49.3 ± 16.6 years; P < 0.0001), no statin exposure (0% vs. 30%, P = 0.014), and more neck flexor weakness (66.7% vs. 34%; P = 0.022). The atypical group exhibited ragged red fibers (13.3%), COX-negative fibers (26.7%) in patients under 60 years old, lipid aggregation (13.3%), glycogen accumulation (20%), and rimmed vacuoles (46.7%). Additionally, patients with atypical IMNM had a longer time to remission (Log-rank P = 0.033) and more frequently experienced chronic continuous courses (60% vs. 20.5%; P = 0.040) compared with the patients with typical IMNM. Conclusion Anti-HMGCR-positive IMNM patients with atypical clinicopathological manifestations had worse prognosis and poor response to treatment compared to those with typical patterns, which suggest these patients may have distinct pathogenesis and need to find novel therapy.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: